Multicenter retrospective and prospective observational study based on the collection of sequential anonymized data from principal Italian ITP centers, to describe the clinical course of ITP patients becoming infected by SARS-CoV-2 and of COVID-19 patients developing de novo ITP.
Multicenter retrospective and prospective observational study based on the collection - through pre-piloted electronic CRFs - of sequential anonymized data from principal Italian ITP centers representative of national geographical distribution, to evaluate, during a 2-years study period, both the cumulative incidence COVID-19 occurring in patients with prior or ongoing ITP (COVID-19 in ITP) and the cumulative incidence of de novo ITP manifesting during COVID-19 (ITP in COVID-19). Data will be collected to describe the clinical course of patients in the two groups. The enrolment period will last 24 months or terminate at the last day of 1-month-COVID-19 free in Italy, whichever comes first. Each patient will be followed up to the first visit scheduled as per common center practice, including at least six months after hospital discharge or end of quarantine home confinement.
Study Type
OBSERVATIONAL
Enrollment
140
ASST Degli Spedali Civili Di Brescia - UO Ematologia
Brescia, Italy
RECRUITINGUnità di Onco-Ematologia - Azienda Ospedaliera Garibaldi
Catania, Italy
RECRUITINGA.O.U. Careggi - Ematologia
Florence, Italy
RECRUITINGAOU San Luigi Gonzaga - SCDU Ematologia Generale E Oncoematologia
Orbassano, Italy
RECRUITINGPoliclinico Universitario Agostino Gemelli
Roma, Italy
RECRUITINGEmatologia Città della Salute e della Scienza di Torino - Molinette
Torino, Italy
RECRUITINGASST Dei Sette Laghi - UOC Ematologia
Varese, Italy
RECRUITINGAOU Integrata Di Verona, Policlinico G.B. Rossi - UOC Ematologia
Verona, Italy
RECRUITINGNumber of ITP patients in which COVID-19 occurs
Cumulative incidence of COVID-19 in adult patients with already known/ongoing ITP
Time frame: 24 months
Number of COVID-19 patients developing ITP
Cumulative incidence of adult patients with COVID-19 developing de novo ITP
Time frame: 24 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.